AngioDynamics replaces CEO
AngioDynamics has appointed Jan Keltjens as president and CEO, replacing its co-founder Eamonn Hobbs, who will become vice chairman of the board, effective March 1.
Most recently, Keltjens was president and CEO of medical technology company CryoCath Technologies. Prior to that, Keltjens served in various positions at Cordis, a Johnson & Johnson company, including worldwide general manager of Cordis Neurovascular, vice president of European marketing and worldwide strategic marketing for Cordis Cardiology, according to the Queensbury, N.Y.-based AngioDynamics.
“Jan's appointment is the culmination of an extensive search for the best candidate to build on the successes of Eamonn's founding leadership and take us to the next level in the Company's growth and development,” said AngioDynamics’ Chairman Vincent Bucci.
Most recently, Keltjens was president and CEO of medical technology company CryoCath Technologies. Prior to that, Keltjens served in various positions at Cordis, a Johnson & Johnson company, including worldwide general manager of Cordis Neurovascular, vice president of European marketing and worldwide strategic marketing for Cordis Cardiology, according to the Queensbury, N.Y.-based AngioDynamics.
“Jan's appointment is the culmination of an extensive search for the best candidate to build on the successes of Eamonn's founding leadership and take us to the next level in the Company's growth and development,” said AngioDynamics’ Chairman Vincent Bucci.